Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.
Journal for immunotherapy of cancer（2018）
摘要
ClinicalTrials.gov, NCT02437916 .
更多查看译文
关键词
Agonistic antibody,Antibodies,monoclonal,Clinical trial,phase 1,Dose,maximum tolerated,Glucocorticoid-induced TNFR-related protein
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要